Antibodies Against SARS-CoV-2 Nucleocapsid Protein Possess Autoimmune Properties.

ABSTRACT:

Background/objectives

Notwithstanding the declaration by the World Health Organization in May 2023 regarding the conclusion of the COVID-19 pandemic, new cases of this potentially lethal infection continue to be documented globally, exerting a sustained influence on the worldwide economy and social structures. Contemporary SARS-CoV-2 variants, while associated with a reduced propensity for severe acute pathology, retain the capacity to induce long-term post-COVID syndrome, including in ambulatory patient populations. This clinical phenomenon may be attributable to potential autoimmune reactions hypothetically triggered by antiviral antibodies, thereby underscoring the need for developing novel, universal vaccines against COVID-19. The nucleocapsid protein (N), being one of its most

SUBMITTER: Rak A 

PROVIDER: S-EPMC12821584 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature